COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

RECENT NEWS

Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
Nov 13 2026, 8:30 AM EST

Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
Nov 4 2026, 9:20 AM EST

STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	3.89m
Last Price	$1.66
52-Week Range	$1.5801 - $4.9392

11/13/2026 08:34 PM EST

INVESTOR RELATIONS

JTC Team, LLC.
Jenene Thomas
T: 908-824-0775
xbio@jtcir.com

MANAGEMENT TEAM

James F. Parslow
Interim Chief Executive Officer and Chief Financial Officer

Scott N. Cullison
Business Development

Reid P. Bissonnette, Ph.D.
Translational Research and Development

XENETIC BIOSCIENCES, INC.

945 Concord Street
Framingham, MA 01701
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.